0.9152

1.25% -0.0116

After Hours: .92 0.0048 +0.52%

Rapt Therapeutics Inc (RAPT)

Overview News Price History Option Chain Financials Discussions Forecast

Rapt Therapeutics Inc stock is traded at $0.9152, with a volume of 766.33K. It is down -1.25% in the last 24 hours and down -21.78% over the past month. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Previous Close:

$0.9268

Open:

$0.92

24h Volume:

766.33K

Relative Volume:

1.03

Market Cap:

$115.43M

Revenue:

$3.25M

Net Income/Loss:

$-116.80M

P/E Ratio:

-0.3001

EPS:

-3.05

Net Cash Flow:

$-98.17M

1W Performance:

+4.67%

1M Performance:

-21.78%

6M Performance:

-58.96%

1Y Performance:

-88.81%

1-Day Range:

$0.851

$0.935

1-Week Range:

$0.8168

$0.9796

52-Week Range:

$0.7535

$8.58

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name

Rapt Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (662)

Phone

(650) 489-9000

Address

561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RAPT's Discussions on Twitter

Compare RAPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPT Rapt Therapeutics Inc	0.9152	115.43M	3.25M	-116.80M	-98.17M	-3.05
VRTX Vertex Pharmaceuticals Inc	498.86	126.60B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	590.00	64.75B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	639.90	36.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.13	31.40B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	102.43	28.98B	2.98B	-717.57M	-264.74M	-2.9987

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-26-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-13-24	Downgrade	Stifel	Buy → Hold
Nov-11-24	Downgrade	JP Morgan	Neutral → Underweight
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Barclays	Overweight → Equal Weight
May-10-24	Downgrade	Guggenheim	Buy → Neutral
Feb-22-24	Downgrade	UBS	Buy → Neutral
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform
Sep-14-23	Initiated	Berenberg	Buy
Aug-09-23	Initiated	Stifel	Buy
Jun-15-23	Initiated	Barclays	Overweight
Jan-04-23	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	CapitalOne	Overweight
May-24-22	Resumed	Cantor Fitzgerald	Overweight
Dec-09-21	Initiated	JP Morgan	Overweight
Aug-12-21	Initiated	SVB Leerink	Outperform
Jun-21-21	Initiated	Piper Sandler	Overweight
Jun-01-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Cantor Fitzgerald	Overweight
Apr-13-20	Initiated	ROTH Capital	Buy
Nov-25-19	Initiated	BMO Capital Markets	Outperform
Nov-25-19	Initiated	UBS	Buy
Nov-25-19	Initiated	Wells Fargo	Outperform

View All

Rapt Therapeutics Inc Stock (RAPT) Latest News

09:24 AM

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com

09:24 AM

07:41 AM

Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX

07:41 AM

03:32 AM

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World

03:32 AM

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 24, 2025